Skip to Content
Merck
All Photos(2)

Documents

Safety Information

06-926

Sigma-Aldrich

Anti-p70 S6 Kinase (S6K) Antibody

Upstate®, from rabbit

Synonym(s):

RPS6KB1, PS6K, S6K, S6K1, STK14A, p70(S6K)-alpha, p70-S6K, p70-alpha, ribosomal protein S6 kinase, 70kDa

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

rabbit

antibody form

purified antibody

antibody product type

primary antibodies

clone

polyclonal

species reactivity

rat, human, mouse

manufacturer/tradename

Upstate®

technique(s)

western blot: suitable

isotype

IgG

NCBI accession no.

NM_003161

UniProt accession no.

Q9UBS0

shipped in

dry ice

target post-translational modification

unmodified

Gene Information

human ... POTEM(641455)

Specificity

p70 S6 kinase

Immunogen

peptide (C-FPMISKRPEHLRMNL) corresponding to residues 511-525 of rat S6 kinase

Application

Anti-p70 S6 Kinase (S6K) Antibody detects level of p70 S6 Kinase (S6K) & has been published & validated for use in WB.
Research Category
Signaling
Research Sub Category
PI3K, Akt, & mTOR Signaling

Quality

routinely evaluated by immunoblot on RIPA lysates from mouse 3T3 cells

Target description

64kDa

Physical form

0.1M Tris-glycine, pH 7.4, 0.15M NaCl, 0.05% sodium azide before the additional of glycerol to 30%
Format: Purified
Protein A chromatography

Storage and Stability

2 years at -20°C

Analysis Note

Control
Positive Antigen Control: Catalog #12-305, 3T3/A31 lysate. Add 2.5 μL of 2-mercapto-ethanol/100 μL of lysate and boil for 5 minutes to reduce the preparation. Load 20 μg of reduced lysate per lane for minigels.

Legal Information

UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

10 - Combustible liquids

WGK

WGK 1

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

JAN Code

06-926:

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Activation of an S6 kinase from human placenta by autophosphorylation.
Dennis, P B and Masaracchia, R A
The Journal of Biological Chemistry, 268, 19833-19841 (1993)
SWI/SNF chromatin remodeling enzyme ATPases promote cell proliferation in normal mammary epithelial cells.
Cohet, N; Stewart, KM; Mudhasani, R; Asirvatham, AJ; Mallappa, C; Imbalzano, KM; Weaver et al.
Journal of Cellular Physiology null
Quan-Yu Zhang et al.
Hepatology (Baltimore, Md.), 66(3), 834-854 (2017-05-17)
Cellular repressor of E1A-stimulated genes (CREG), a novel cellular glycoprotein, has been identified as a suppressor of various cardiovascular diseases because of its capacity to reduce hyperplasia, maintain vascular homeostasis, and promote endothelial restoration. However, the effects and mechanism of
D Chen et al.
Molecular and cellular biology, 19(7), 4684-4694 (1999-06-22)
We have previously reported that insulin and osmotic shock stimulate an increase in glucose transport activity and translocation of the insulin-responsive glucose transporter isoform GLUT4 to the plasma membrane through distinct pathways in 3T3L1 adipocytes (D. Chen, J. S. Elmendorf
Tingting Sun et al.
Aging, 12(23), 24208-24218 (2020-11-24)
The 5-year survival rate of ovarian cancer patients is only 47%, and developing novel drugs for ovarian cancer is needed. Herein, we evaluated if and how SRT2183, a sirtuin-1 activator, impairs the ovarian cancer cells. OVCAR-3 and A2780 cells were
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service